CY1123218T1 - Διαβιβαστης γονιδιου - Google Patents
Διαβιβαστης γονιδιουInfo
- Publication number
- CY1123218T1 CY1123218T1 CY20201100405T CY201100405T CY1123218T1 CY 1123218 T1 CY1123218 T1 CY 1123218T1 CY 20201100405 T CY20201100405 T CY 20201100405T CY 201100405 T CY201100405 T CY 201100405T CY 1123218 T1 CY1123218 T1 CY 1123218T1
- Authority
- CY
- Cyprus
- Prior art keywords
- gene transfer
- hspc
- hsc
- nucleotide sequence
- cell
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 4
- 108091070501 miRNA Proteins 0.000 abstract 2
- 239000002679 microRNA Substances 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17412409P | 2009-04-30 | 2009-04-30 | |
| PCT/IB2010/001166 WO2010125471A2 (en) | 2009-04-30 | 2010-04-30 | Gene vector |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123218T1 true CY1123218T1 (el) | 2021-10-29 |
Family
ID=42790671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100405T CY1123218T1 (el) | 2009-04-30 | 2020-05-04 | Διαβιβαστης γονιδιου |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10287579B2 (enExample) |
| EP (2) | EP2424571B1 (enExample) |
| JP (2) | JP6144911B2 (enExample) |
| KR (1) | KR101793615B1 (enExample) |
| CN (1) | CN102596255B (enExample) |
| AU (1) | AU2010243276B2 (enExample) |
| BR (1) | BRPI1010873B1 (enExample) |
| CA (1) | CA2759438C (enExample) |
| CY (1) | CY1123218T1 (enExample) |
| DK (1) | DK2424571T3 (enExample) |
| EA (1) | EA023938B1 (enExample) |
| ES (1) | ES2786039T3 (enExample) |
| HR (1) | HRP20200647T1 (enExample) |
| HU (1) | HUE049845T2 (enExample) |
| IL (1) | IL215804A (enExample) |
| LT (1) | LT2424571T (enExample) |
| MX (1) | MX2011011508A (enExample) |
| PL (1) | PL2424571T3 (enExample) |
| PT (1) | PT2424571T (enExample) |
| SG (2) | SG10201610827RA (enExample) |
| SI (1) | SI2424571T1 (enExample) |
| SM (1) | SMT202000224T1 (enExample) |
| WO (1) | WO2010125471A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2424571T1 (sl) * | 2009-04-30 | 2020-10-30 | Ospedale San Raffaele S.R.L. | Genski vektor |
| LT2772265T (lt) | 2010-05-14 | 2018-05-25 | Oregon Health & Science University | Rekombinantiniai žcmv ir rhcmv vektoriai ir jų panaudojimas |
| WO2012006577A2 (en) * | 2010-07-08 | 2012-01-12 | Duke University | Direct reprogramming of cells to cardiac myocyte fate |
| GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
| WO2013152230A1 (en) * | 2012-04-04 | 2013-10-10 | The Trustees Of Columbia University In The City Of New York | Smooth muscle specific inhibition for anti-restenotic therapy |
| US10266850B2 (en) | 2012-05-25 | 2019-04-23 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| JP6329537B2 (ja) | 2012-07-11 | 2018-05-23 | サンガモ セラピューティクス， インコーポレイテッド | 生物学的薬剤の送達のための方法および組成物 |
| CA3034794A1 (en) | 2012-12-06 | 2014-06-12 | Sigma-Aldrich Co. Llc | Crispr-based genome modification and regulation |
| RS64664B1 (sr) | 2013-02-15 | 2023-11-30 | Bioverativ Therapeutics Inc | Gen optimizovanog faktora viii |
| DK3620534T3 (da) | 2013-03-14 | 2021-12-06 | Caribou Biosciences Inc | Crispr-cas sammensætninger af nucleinsyre-targeting nucleinsyrer |
| CA2927712A1 (en) | 2013-10-24 | 2015-04-30 | Ospedale San Raffaele S.R.L. | Method for the genetic modification of haematopoietic stem and progenitor cells (hspcs) and the use of genetically modified hspcs in gene therapy |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| US10501811B2 (en) | 2015-04-22 | 2019-12-10 | Kyoto University | Method for sorting tissue cells |
| WO2016201507A1 (en) * | 2015-06-15 | 2016-12-22 | Murdoch Childrens Research Institute | Method of measuring chimerism |
| JP6990176B2 (ja) | 2015-10-05 | 2022-02-03 | モデルナティエックス インコーポレイテッド | メッセンジャーリボ核酸薬物の治療投与のための方法 |
| US10188750B1 (en) | 2015-10-23 | 2019-01-29 | University Of South Florida | Self-replicating cell selective gene delivery compositions, methods, and uses thereof |
| PH12018501628B1 (en) | 2016-02-01 | 2023-11-10 | Bioverativ Therapeutics Inc | Optimized factor viii genes |
| GB201612214D0 (en) | 2016-07-14 | 2016-08-31 | Univ Oxford Innovation Ltd | Method |
| US10457940B2 (en) | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
| CR20190205A (es) * | 2016-10-18 | 2020-01-07 | Univ Oregon Health & Science | Vectores de citomegalovirus que provocan células t restringidas por moléculas del complejo mayor de histocompatibilidad e |
| CN106566838B (zh) * | 2016-11-14 | 2019-11-01 | 上海伯豪生物技术有限公司 | 一种基于CRISPR-Cas9技术的miR-126全长基因敲除试剂盒及其应用 |
| EP4491233A3 (en) * | 2017-04-21 | 2025-04-16 | Ospedale San Raffaele S.r.l. | Gene therapy |
| IT201700086403A1 (it) * | 2017-07-27 | 2019-01-27 | Univ Del Piemonte Orientale | Endothelial-specific promoter sequences and uses thereof |
| NZ762100A (en) | 2017-08-09 | 2025-12-19 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof |
| JP2021512126A (ja) | 2018-02-01 | 2021-05-13 | バイオベラティブ セラピューティクス インコーポレイテッド | 第ｖｉｉｉ因子を発現するレンチウイルスベクターの使用 |
| EP3833766A1 (en) | 2018-08-09 | 2021-06-16 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| CN113396223A (zh) | 2018-12-06 | 2021-09-14 | 比奥维拉迪维治疗股份有限公司 | 表达因子ix的慢病毒载体的用途 |
| CN115279896A (zh) | 2019-09-30 | 2022-11-01 | 比奥维拉迪维治疗股份有限公司 | 慢病毒载体配制品 |
| US20220378937A1 (en) * | 2019-11-12 | 2022-12-01 | The Regents Of The University Of California | Lentiviral vectors in hematopoietic stem cells to treat x-linked chronic granulomatous disease |
| IL299333A (en) | 2020-06-24 | 2023-02-01 | Bioverativ Therapeutics Inc | Methods for the purification of viral vectors |
| CN116194152A (zh) | 2020-08-23 | 2023-05-30 | 比奥维拉迪维治疗股份有限公司 | 用于改进封闭端DNA（ceDNA）的产生的经修饰的杆状病毒系统 |
| EP4392566A2 (en) | 2021-08-23 | 2024-07-03 | Bioverativ Therapeutics Inc. | Baculovirus expression system |
| AU2022332276A1 (en) | 2021-08-23 | 2024-04-04 | Bioverativ Therapeutics Inc. | Optimized factor viii genes |
| WO2023056331A1 (en) | 2021-09-30 | 2023-04-06 | Bioverativ Therapeutics Inc. | Nucleic acids encoding factor viii polypeptides with reduced immunogenicity |
| MA71632A (fr) * | 2022-07-25 | 2025-05-30 | Modernatx, Inc. | Polynucléotides modifiés pour l'expression sélective de cellules |
| WO2025122739A1 (en) * | 2023-12-05 | 2025-06-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Compositions and methods for treating a heart disease |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5723315A (en) | 1996-08-23 | 1998-03-03 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| KR20000029858A (ko) | 1996-08-07 | 2000-05-25 | 마르크 젠너 | 엠엠피와티엔에프억제활성을갖는히드록삼산및카르복실산유도체 |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| NZ532060A (en) * | 2001-10-02 | 2005-11-25 | Inst Clayton De La Rech | Methods and compositions relating to restricted expression lentiviral vectors and their applications |
| EP2474616B1 (en) | 2004-05-28 | 2015-07-08 | Asuragen, Inc. | Methods and compositions involving microRNA |
| US20060134784A1 (en) * | 2004-11-30 | 2006-06-22 | Basch Ross S | Methods and compositions for the growth and maintenance of stem cells |
| KR20130114758A (ko) * | 2005-05-27 | 2013-10-17 | 오스페달레 산 라파엘 에스.알.엘. | Ｍｉ-ｒｎａ를 포함하는 유전자 벡터 |
| JP2008541737A (ja) * | 2005-06-03 | 2008-11-27 | サウザーン アデレード ヘルス サービス−ファインダーズ メディカル センター | マイクロｒｎａ発現の変化した細胞を標的とすること |
| US20090180989A1 (en) * | 2005-10-05 | 2009-07-16 | Synageva Biopharma Corp. | Compositions and methods for delivering nucleotide sequences to vertebrates |
| EP2487254B1 (en) | 2006-01-05 | 2015-07-29 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers |
| US20080095750A1 (en) | 2006-05-10 | 2008-04-24 | Pennington Biomedical Research Center, Louisiana State University System | Use of adipose-derived stem cells for treatment of leukodystrophies |
| CA2671296A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mir-126 regulated genes and pathways as targets for therapeutic intervention |
| EP3252161B1 (en) | 2007-06-06 | 2021-11-17 | Genzyme Corporation | Gene therapy for lysosomal storage diseases |
| WO2010055413A1 (en) | 2008-11-12 | 2010-05-20 | Fondazione Centro San Raffaele Del Monte Tabor | Gene vector for inducing transgene-specific immune tolerance |
| SI2424571T1 (sl) | 2009-04-30 | 2020-10-30 | Ospedale San Raffaele S.R.L. | Genski vektor |
-
2010
- 2010-04-30 SI SI201032001T patent/SI2424571T1/sl unknown
- 2010-04-30 PT PT107233058T patent/PT2424571T/pt unknown
- 2010-04-30 WO PCT/IB2010/001166 patent/WO2010125471A2/en not_active Ceased
- 2010-04-30 DK DK10723305.8T patent/DK2424571T3/da active
- 2010-04-30 SG SG10201610827RA patent/SG10201610827RA/en unknown
- 2010-04-30 HR HRP20200647TT patent/HRP20200647T1/hr unknown
- 2010-04-30 KR KR1020117028569A patent/KR101793615B1/ko active Active
- 2010-04-30 EP EP10723305.8A patent/EP2424571B1/en active Active
- 2010-04-30 JP JP2012507847A patent/JP6144911B2/ja active Active
- 2010-04-30 AU AU2010243276A patent/AU2010243276B2/en active Active
- 2010-04-30 MX MX2011011508A patent/MX2011011508A/es active IP Right Grant
- 2010-04-30 BR BRPI1010873A patent/BRPI1010873B1/pt active IP Right Grant
- 2010-04-30 LT LTEP10723305.8T patent/LT2424571T/lt unknown
- 2010-04-30 CN CN201080030337.7A patent/CN102596255B/zh active Active
- 2010-04-30 US US13/266,381 patent/US10287579B2/en active Active
- 2010-04-30 CA CA2759438A patent/CA2759438C/en active Active
- 2010-04-30 SM SM20200224T patent/SMT202000224T1/it unknown
- 2010-04-30 EA EA201171335A patent/EA023938B1/ru not_active IP Right Cessation
- 2010-04-30 HU HUE10723305A patent/HUE049845T2/hu unknown
- 2010-04-30 EP EP20167404.1A patent/EP3733214A1/en active Pending
- 2010-04-30 ES ES10723305T patent/ES2786039T3/es active Active
- 2010-04-30 SG SG2011080009A patent/SG175839A1/en unknown
- 2010-04-30 PL PL10723305T patent/PL2424571T3/pl unknown
-
2011
- 2011-10-23 IL IL215804A patent/IL215804A/en active IP Right Grant
-
2015
- 2015-09-07 JP JP2015175986A patent/JP6370278B2/ja active Active
-
2017
- 2017-08-31 US US15/693,112 patent/US9951328B2/en active Active
-
2019
- 2019-04-15 US US16/384,571 patent/US11407996B2/en active Active
-
2020
- 2020-05-04 CY CY20201100405T patent/CY1123218T1/el unknown
-
2022
- 2022-06-30 US US17/855,135 patent/US20220333103A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123218T1 (el) | Διαβιβαστης γονιδιου | |
| MX356625B (es) | Oligonucleotidos para elaborar un cambio en la secuencia de una molécula de ácido ribonucleico objetivo presente en una célula viva. | |
| MX2017004039A (es) | Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso. | |
| MX2014003979A (es) | Nucleosidos, nucleotidos, y acidos nucleicos modificados, y usos de los mismos. | |
| CY1120560T1 (el) | Βελτιστοποιημενο συστημα παραδοσης in vivo me ενδοσωματολυτικους παραγοντες για συζευγματα νουκλεϊνικου οξεος | |
| CY1118215T1 (el) | Αντι-νεοπλασματικη ανοσοθεραπεια | |
| PH12015502799A1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| NZ753018A (en) | Conjugated antisense compounds and their use | |
| MX339822B (es) | Derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento contra el cancer. | |
| MX2016005488A (es) | Vector hsv oncolitico. | |
| WO2014191359A9 (en) | Aptamers and use of the aptamers in the diagnosis and treatment of cancer | |
| EP2494035A4 (en) | PLURIPOTENT STEM CELLS | |
| UY33647A (es) | ?agentes de unión a cd33?. | |
| IN2014DN08831A (enExample) | ||
| HUE036872T2 (hu) | Kiméra, antigénreceptor-módosított T-sejt alkalmazása rák kezelésére | |
| EA201692318A1 (ru) | Композиции и способы для ингибирования экспрессии гена альфа-1-антитрипсина | |
| CY1123144T1 (el) | Επαγωγη καρδιακης αναγεννησης μe microrna | |
| EA201890598A2 (ru) | Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты | |
| TR201909747T4 (tr) | Aktarım. | |
| CY1120084T1 (el) | Oλiγονουκλεοτiδiα για τη ρυθμιση της γονιδιακης εκφρασης και οι χρησεις αυτων | |
| UA107476C2 (uk) | Фармацевтична субстанція на основі мітохондріально адресованих антиоксидантів | |
| MY196912A (en) | Short pendant arm linkers for nucleotides in sequencing applications | |
| BR112018070249A2 (pt) | sistema promotor de u6 modificada para expressão específica de tecido | |
| BR112014029157A2 (pt) | carregador de pistola curvado lateralmente | |
| BR112015008381A2 (pt) | aquecedor portátil ativado por oxigênio com almofada de eletrólito |